Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.
Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lantheus (LNTH – Research Report) and Argenx Se ...
Lantheus Holdings Inc (LNTH) reports robust sales growth for PYLARIFY and DEFINITY, while navigating increased operating ...
Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...
Lantheus (NASDAQ:LNTH – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, ...
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting earnings tomorrow before market hours. Here’s ...
Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback